The ER520 selective estrogen receptor modulator decreased breast and endometrial cancer cell adhesion, migration, and invasion as well as VEGF secretion and disrupted HUVEC-C tube-forming ability [46]. This evidence concerns the gene ESR1 and endometrial cancer.